This HTML5 document contains 30 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n11http://linked.opendata.cz/resource/drugbank/drug/DB05413/identifier/drugbank/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB05413/identifier/chemspider/
n9http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n6http://linked.opendata.cz/resource/drugbank/drug/DB05413/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05413
rdf:type
n3:Drug
n3:description
T-1249 is the first members of a new class of anti-HIV drugs which is also called fusion inhibitors. It has received fast track designation from the FDA and is in Phase I/II clinical testing.
n3:group
investigational
n3:indication
Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection.
owl:sameAs
n9:DB05413
dcterms:title
T-1249
adms:identifier
n6:16130644 n10:17287364 n11:DB05413
n3:mechanismOfAction
T-1249 binds to a slightly different region of the HIV virus than Fuzeon (enfuvirtide). As a result,it exhibits activity against Fuzeon-resistant viruses. T-1249 is designed to block fusion of HIV with host cells before the virus enters the cell and begins its replication process.
n3:IUPAC-Name
n4:271B42F1-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B42F6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B42F3-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B42F4-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B42F5-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B42F0-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B42FB-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B42FC-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B42F7-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B42F8-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B42F9-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B42FA-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4300-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4302-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4303-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B42FF-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B42FE-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4301-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B42F2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B42FD-363D-11E5-9242-09173F13E4C5